Mr. Gould is a Senior Principal in CBPartners' Value, Access, and Pricing practice, where he leads the U.S. Center of Excellence and focuses on managed markets strategy engagements. His experience has emphasized the development of numerous pricing and access strategies for both pre-launch and in-line assets within the U.S. Specifically, Mr. Gould supports asset development through various engagements, including: early stage / launch pricing, innovative and traditional contracting strategy, market access assessment, target product profile & optimized trial design review, and value message development / testing.
Mr. Gould also has extensive experience engaging with payers and other healthcare stakeholders through various qualitative research methodologies, including in-depth interviews, dyads, live panels / ad-boards, and virtual panels. Additionally, he has led engagements involving quantitative surveys and comprehensive data analyses.
Prior to joining CBPartners, Mr. Gould spent over five years with PriceSpective (ICON). Mr. Gould holds a MS in Biotechnology from Middle Tennessee State University and a BS in Biomedical Science from Auburn University.
Connect with Andrew Gould
Since its inception over 30 years ago, the 340B drug pricing program policy has evolved allowing for unprecedented expansion and influence. With this it has also become highly contested, especially in recent years as more legislation has been put forward to close 340B loopholes.
Andrew Gould asks our US payer panel for their expert perspectives surrounding the management of tumor-agnostic therapies.
A research poster identifying the impact of utilizing Integrated Delivery Networks and their in-house resources in fulfilling HEOR program requirements.
A research poster identifying instances where manufacturer HEOR data and/or pharmacoeconomic models either influenced positive changes, or had limited tangible impact on resultant US payer coverage decisions.
Andrew Gould asks our US payer panel for their expert perspectives surrounding the management of gene therapies, both now and in the future.
Andrew Gould asks our US payer panel for their expert perspectives surrounding pricing for uncertain future indications.
US Market Access Trends: CBPartners' Andrew Gould asks a panel of US payers what is the likelihood of increased site-of-care-restrictions is among them.